Sandoz’s Anti-VEGF Biosimilar Secures FDA Approval for nAMD Treatment
On August 12, 2024, Sandoz (Basel, Switzerland), a generic and biosimilar pharmaceuticals company, has received FDA approval for Enzeevu™ (aflibercept-abzv,…
On August 12, 2024, Sandoz (Basel, Switzerland), a generic and biosimilar pharmaceuticals company, has received FDA approval for Enzeevu™ (aflibercept-abzv,…